David Altshuler - Nov 7, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Nov 7, 2022
Transactions value $
-$150,507
Form type
4
Date filed
11/9/2022, 03:40 PM
Previous filing
Aug 10, 2022
Next filing
Nov 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $244K +1.3K +3.61% $187.53 37.4K Nov 7, 2022 Direct
transaction VRTX Common Stock Sale -$42K -140 -0.37% $299.72 37.2K Nov 7, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$63.2K -210 -0.56% $300.96 37K Nov 7, 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$57.1K -189 -0.51% $301.99 36.8K Nov 7, 2022 Direct F1, F2, F5
transaction VRTX Common Stock Sale -$79.1K -261 -0.71% $303.21 36.6K Nov 7, 2022 Direct F1, F2, F6
transaction VRTX Common Stock Sale -$85.3K -280 -0.77% $304.58 36.3K Nov 7, 2022 Direct F1, F2, F7
transaction VRTX Common Stock Sale -$42.8K -140 -0.39% $305.39 36.2K Nov 7, 2022 Direct F1, F2, F8
transaction VRTX Common Stock Sale -$25.4K -83 -0.23% $306.57 36.1K Nov 7, 2022 Direct F1, F2, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1.3K -49.98% $0.00 1.3K Nov 7, 2022 Common Stock 1.3K $187.53 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97).
F4 Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18).
F5 Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20).
F6 Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45).
F7 Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91).
F8 Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39).
F9 Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22).
F10 The option vests in 16 quarterly installments from 2/6/2019.